Novartis (NVS)
(Delayed Data from NYSE)
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
The Zacks Analyst Blog Highlights Johnson & Johnson, Toyota Motor, Infosys, Novartis and Equinix
by Zacks Equity Research
Johnson & Johnson, Toyota Motor, Infosys, Novartis and Equinix are part of the Zacks top Analyst Blog.
Novartis (NVS) Oncology Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Novartis (NVS) obtains FDAs approval for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) for pediatric brain cancer.
Top Stock Reports for Johnson & Johnson, Toyota Motor & Infosys
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Toyota Motor Corporation (TM) and Infosys Limited (INFY).
Novartis (NVS) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why
by Zacks Equity Research
Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.
Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi
by Zacks Equity Research
J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.
Here's Why Novartis (NVS) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Large Drug Stocks to Watch as Sector Picks Up in 2023
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.
Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer
by Zacks Equity Research
Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.
Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study
by Zacks Equity Research
Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.
Zacks.com featured highlights Sanofi, SK Telecom, PBF Energy, Arrow Electronics and Novartis
by Zacks Equity Research
Sanofi, SK Telecom, PBF Energy, Arrow Electronics and Novartis have been highlighted in this Screen of The Week article.
AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study
by Zacks Equity Research
AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.
These 5 Price-to-Sales Stocks Can Be Rewarding Investments
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SNY, SKM, PBF, ARW and NVS hold promise.
NVS vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
After Plunging -7.17% in 4 Weeks, Here's Why the Trend Might Reverse for Novartis (NVS)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Novartis (NVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak
by Zacks Equity Research
Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.
Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.
Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA
by Zacks Equity Research
The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.
Incyte (INCY) Reports Positive Long-Term Data From HS Study
by Zacks Equity Research
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy
by Zacks Equity Research
Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Weibo and Viasat have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Weibo and Viasat are part of the Zacks Bull and Bear of the Day article.